MUC1 and squamous cell carcinoma: In future clinical trials or practice, smoking status should be taken into account for the other two types of drugs, the anti-UTLA-4 and anti-MUC1; (3) smoking status may be considered as a clinical predictor in the treatment with a combination of these three drugs; and 4) clinical smoking history is important in lung cancer, head neck, and bladder cancer because they are associated with squamous carcinoma.